Wednesday, July 1, 2026 Live from SEC EDGAR

The Wire Search Saved

···

FilingIndex

AI-powered intelligence over every SEC filing. Search in plain English. Free.

Browse

Sectors
Themes
Search

Data

SEC EDGAR
About

Legal

Privacy
Disclaimer

© 2026 FilingIndex · Data sourced from SEC EDGAR (public domain).Not investment advice.

PRPH — ProPhase Labs, Inc. SEC Filings | FilingIndex

PRPHOTC

ProPhase Labs, Inc.

Pharmaceutical Preparations · DE · CIK 868278

ProPhase Labs develops and markets diagnostic tests and supplements

+ Watch View on EDGAR ↗

489

Total filings

Jun 30, 2026

Last filing

12/31

Fiscal year end

All 8-K · 281 10-Q · 85 DEF 14A · 34 10-K · 28 DEFA14A · 14 8-K/A · 14 424B5 · 11 SC 13D · 8

DEF 14ADEF 14AOct 31, 2025 DEF 14ADEF 14AAug 15, 2025 DEF 14ADEF 14AJun 23, 2025 DEF 14ADEF 14AMay 15, 2024 DEF 14ADEF 14AApr 27, 2023 DEF 14A

Similar companies

Comparable business profile · signals at a glance

LIXTLIXTE BIOTECHNOLOGY HOLDINGS, INC.$107.6M-7.7%FLGTFulgent Genetics, Inc.$530.5M-0.1%CTNMContineum Therapeutics, Inc.$444.2M+9.3%LRMRLarimar Therapeutics, Inc.$360.5M-4.7%SLSSELLAS Life Sciences Group, Inc.

DEF 14A

Apr 13, 2022

DEF 14ADEF 14AApr 16, 2021

DEF 14ADEF 14AApr 16, 2020

DEF 14ADEF 14AApr 19, 2019

DEF 14ADEF 14AApr 19, 2018

DEF 14ADEF 14AMar 23, 2018

DEF 14ADEF 14AApr 20, 2017

DEF 14ADEF 14AMar 3, 2017

DEF 14ADEF 14AApr 18, 2016

DEF 14ADEF 14AMay 11, 2015

DEF 14ADEF 14AApr 9, 2014

DEF 14ADEF 14AApr 3, 2013

DEF 14ADEFINITIVE PROXY STATEMENTMar 14, 2012

DEF 14ADEF 14AMar 16, 2011

DEF 14ADEF 14AApr 2, 2010

DEF 14ADEF 14AApr 2, 2009

DEF 14ADEF 14AApr 4, 2008

DEF 14ADEF 14AApr 17, 2007

DEF 14ADEF 14AMay 1, 2006

DEF 14ADEF 14AMay 2, 2005

DEF 14ADEF 14AApr 29, 2004

DEF 14ADEF 14AMar 31, 2003

DEF 14ADEF 14AMar 26, 2002

DEF 14ADEFINITIVE PROXYApr 2, 2001

DEF 14APROXY STATEMENTMar 31, 2000

DEF 14ADEFINITIVE PROXY STATEMENTSep 14, 1999

DEF 14ADEFINITIVE PROXY STATEMENTMar 23, 1999

DEF 14APROXY STATEMENTApr 3, 1998

DEF 14APROXY STATEMENTFeb 24, 1997

$1.5B

-4.5%

INBXInhibrx Biosciences, Inc.$1.4B-0.8%